AstraZeneca Results Presentation Deck
BioPharmaceuticals: Respiratory & Immunology
6% growth with improved year-on-year performance in Q2
$m
1,750
1,500
1,250
1,000
750
500
250
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Respiratory
6% growth
Q1 2019
Q2 2019
Q3 2019
Fasenra Symbicort Pulmicort Other
Total revenue at actual exchange rates; changes
at CER and for H1 2021, unless stated otherwise.
16
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Improved performance with new
medicines offsetting mature ones
US +17%
Symbicort (-5%); H1 2020 inventory
and COVID-19 effect. Fasenra (+31%)
Europe -5%
Symbicort (-12%); partial
offset by Fasenra (+39%)
EROW -14%
Japan: -17%; increasing Symbicort
generic competition. Fasenra (+14%)
EM +10%
Pulmicort ($405m, +2%) ; increased
respiratory infections offset by generic
competition. VBP¹ impact in H2 2021
Maintenance use with Symbicort
($306m, +2%)
11-2018
PBHE
PULMICORT
1 mg/2m
W
Pulmicort 1mg in 2 mL
restules
Sterle single-dose un
user uspersion
1. Volume-based procurement.
5 x 2mL
อาชนทราย ยาเฉพาะ
AstraZeneca.
Fasenra Pen 30 mg/mL
(benvallzumab
Pjection p
Symbicort
3View entire presentation